TC
SNDX icon

TwinBeech Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

TwinBeech Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Sell
28,077
-61,929
-69% -$1.29M 0.11% 206
2026
Q1 		$2.1M Buy
90,006
+37,106
+70% +$806K 0.22% 141
2025
Q4 		$1.11M Buy
52,900
+8,606
+19% +$150K 0.08% 284
2025
Q3 		$681K Sell
44,294
-68,500
-61% -$897K 0.03% 361
2025
Q2 		$1.06M Sell
112,794
-143,038
-56% -$1.57M 0.02% 410
2025
Q1 		$3.14M Sell
255,832
-100,068
-28% -$1.41M 0.06% 324
2024
Q4 		$4.7M Buy
355,900
+157,321
+79% +$2.69M 0.08% 228
2024
Q3 		$3.82M Buy
198,579
+30,865
+18% +$638K 0.07% 300
2024
Q2 		$3.44M Buy
167,714
+95,831
+133% +$2.01M 0.07% 267
2024
Q1 		$1.71M Sell
71,883
-11,573
-14% -$258K 0.04% 361
2023
Q4 		$1.8M Sell
83,456
-104,654
-56% -$1.61M 0.03% 415
2023
Q3 		$2.73M Buy
188,110
+37,914
+25% +$717K 0.05% 363
2023
Q2 		$3.14M Buy
150,196
+20,672
+16% +$430K 0.06% 324
2023
Q1 		$2.74M Buy
+129,524
New +$3.22M 0.06% 330

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

TwinBeech Capital's SNDX Position: Q2 2026 in Review

TwinBeech Capital reduced its Syndax Pharmaceuticals (SNDX) stake by 69% in Q2 2026, selling an estimated $1.29M and leaving 28,077 shares worth $614K. The position accounts for 0.11% of the portfolio, ranked #206.

TwinBeech Capital first reported a position in SNDX in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.7M in Q4 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • TwinBeech Capital held 28,077 shares of Syndax Pharmaceuticals worth $614K as of Q2 2026.
  • TwinBeech Capital sold 61,929 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.29M.
  • Syndax Pharmaceuticals made up 0.11% of TwinBeech Capital's portfolio in Q2 2026, its #206 holding.
  • TwinBeech Capital first reported a position in Syndax Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • TwinBeech Capital's Syndax Pharmaceuticals position peaked at $4.7M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.